Literature DB >> 16320100

Propagation of population pharmacokinetic information using a Bayesian approach: comparison with meta-analysis.

Aristides Dokoumetzidis1, Leon Aarons.   

Abstract

We investigated the propagation of population pharmacokinetic information across clinical studies by applying Bayesian techniques. The aim was to summarize the population pharmacokinetic estimates of a study in appropriate statistical distributions in order to use them as Bayesian priors in consequent population pharmacokinetic analyses. Various data sets of simulated and real clinical data were fitted with WinBUGS, with and without informative priors. The posterior estimates of fittings with non-informative priors were used to build parametric informative priors and the whole procedure was carried on in a consecutive manner. The posterior distributions of the fittings with informative priors where compared to those of the meta-analysis fittings of the respective combinations of data sets. Good agreement was found, for the simulated and experimental datasets when the populations were exchangeable, with the posterior distribution from the fittings with the prior to be nearly identical to the ones estimated with meta-analysis. However, when populations were not exchangeble an alternative parametric form for the prior, the natural conjugate prior, had to be used in order to have consistent results. In conclusion, the results of a population pharmacokinetic analysis may be summarized in Bayesian prior distributions that can be used consecutively with other analyses. The procedure is an alternative to meta-analysis and gives comparable results. It has the advantage that it is faster than the meta-analysis, due to the large datasets used with the latter and can be performed when the data included in the prior are not actually available.

Mesh:

Substances:

Year:  2005        PMID: 16320100     DOI: 10.1007/s10928-005-0048-9

Source DB:  PubMed          Journal:  J Pharmacokinet Pharmacodyn        ISSN: 1567-567X            Impact factor:   2.745


  9 in total

1.  The combination of population pharmacokinetic studies.

Authors:  J Wakefield; N Rahman
Journal:  Biometrics       Date:  2000-03       Impact factor: 2.571

2.  Determination of an optimal dosage regimen using a Bayesian decision analysis of efficacy and adverse effect data.

Authors:  Gordon Graham; Suneel Gupta; Leon Aarons
Journal:  J Pharmacokinet Pharmacodyn       Date:  2002-02       Impact factor: 2.745

3.  Bayesian analysis of population PK/PD models: general concepts and software.

Authors:  David J Lunn; Nicky Best; Andrew Thomas; Jon Wakefield; David Spiegelhalter
Journal:  J Pharmacokinet Pharmacodyn       Date:  2002-06       Impact factor: 2.745

4.  A Bayesian approach to parameter estimation in HIV dynamical models.

Authors:  H Putter; S H Heisterkamp; J M A Lange; F de Wolf
Journal:  Stat Med       Date:  2002-08-15       Impact factor: 2.373

5.  A Bayesian approach to nonlinear random effects models.

Authors:  A Racine-Poon
Journal:  Biometrics       Date:  1985-12       Impact factor: 2.571

6.  Modeling of trough plasma bismuth concentrations.

Authors:  J E Bennett; J C Wakefield; L F Lacey
Journal:  J Pharmacokinet Biopharm       Date:  1997-02

7.  A population analysis of the pharmacokinetics and pharmacodynamics of midazolam in the rat.

Authors:  L Aarons; J W Mandema; M Danhof
Journal:  J Pharmacokinet Biopharm       Date:  1991-10

8.  In vivo characterization of the pharmacodynamic interaction of a benzodiazepine agonist and antagonist: midazolam and flumazenil.

Authors:  J W Mandema; E Tukker; M Danhof
Journal:  J Pharmacol Exp Ther       Date:  1992-01       Impact factor: 4.030

9.  Estimation of population pharmacokinetic parameters in the presence of non-compliance.

Authors:  Song Mu; Thomas M Ludden
Journal:  J Pharmacokinet Pharmacodyn       Date:  2003-02       Impact factor: 2.745

  9 in total
  4 in total

1.  Integration of data from multiple sources for simultaneous modelling analysis: experience from nevirapine population pharmacokinetics.

Authors:  Elin Svensson; Jan-Stefan van der Walt; Karen I Barnes; Karen Cohen; Tamara Kredo; Alwin Huitema; Jean B Nachega; Mats O Karlsson; Paolo Denti
Journal:  Br J Clin Pharmacol       Date:  2012-09       Impact factor: 4.335

2.  Propagation of population PK and PD information using a Bayesian approach: dealing with non-exchangeability.

Authors:  Aristides Dokoumetzidis; Leon Aarons
Journal:  J Pharmacokinet Pharmacodyn       Date:  2005-12-12       Impact factor: 2.745

Review 3.  A survey of population analysis methods and software for complex pharmacokinetic and pharmacodynamic models with examples.

Authors:  Robert J Bauer; Serge Guzy; Chee Ng
Journal:  AAPS J       Date:  2007-03-02       Impact factor: 4.009

4.  Reconstructing population exposures to environmental chemicals from biomarkers: challenges and opportunities.

Authors:  Panos G Georgopoulos; Alan F Sasso; Sastry S Isukapalli; Paul J Lioy; Daniel A Vallero; Miles Okino; Larry Reiter
Journal:  J Expo Sci Environ Epidemiol       Date:  2008-03-26       Impact factor: 5.563

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.